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Background: Biyeom-Tang, a medicine prescribed by oriental clinics, has been used for the treatment of the
allergic rhinitis (AR). In the present study, an ethanol extract of Biyeom-Tang (EBT) was investigated for anti-allergic
properties on bone-marrow derived mast cells (BMMC) and in vivo models.
Methods: The anti-allergic properties of EBT were evaluated by measuring β-Hex release and the production of
prostaglandin D2 (PGD2) and leukotriene C4 (LTC4) on BMMC in vitro and PCA and OVA-induced AR models in vivo.
Results: EBT strongly inhibited a degranulation reaction in a dose dependent manner with an IC50 value of 35.6
μg/ml. In addition, the generation of PGD2 and LTC4 was inhibited in BMMC in a concentration-dependent manner
with IC50 values of 7.0 μg/ml and 10.9 μg/ml, respectively. When administrated orally, EBT ameliorated the mast
cell-mediated PCA reaction. In the OVA-induced AR model, the increased levels of IgE were reduced by EBT.
The levels of cytokines, such as IL-4, IL-5, IL-10, and IL-13 decreased in the splenocytes of EBT-treated mice. The
histological analysis shows that the infiltration of inflammatory cells increased by OVA-sensitization was also
reduced.
Conclusions: Taken together, these results suggested that EBT has anti-allergic and anti-inflammatory effects
in vitro and in vivo models.
Keywords: Biyeom-Tang, Allergic rhinitis (AR), Bone-marrow derived mast cells (BMMC), Passive cutaneous
anaphylaxis (PCA), Degranulation, Prostaglandin D2 (PGD2), Leukotriene C4 (LTC4)Background
Allergic rhinitis (AR) is a common chronic disease of
nasal mucosa characterized by IgE-mediated allergic in-
flammation [1]. Although it is not life-threatening, AR
can deteriorate the quality of life because of the clinical
symptoms including sneezing, rhinorrhea, itching and
nasal congestion. These symptoms are primarily induced
by allergic mediators released from mast cells, basophils,
eosinophils, lymphocytes, and epithelial cells. Among
these cells, mast cells are one of the most important
cells in the allergic response such as AR [2]. When* Correspondence: eklee@ynu.ac.kr
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reproduction in any medium, provided the oractivated, they release a number of biologically active
molecules. Pharmacologically active mediators such as
histamine, prostaglandins (PGs), leukotrienes (LTs) and
cytokines have been known to play a major role in the
pathophysiology of AR.
There are a number of effective therapeutic options,
among which topical corticosteroids are recognized as
the most important and the first line therapy for more
severe and persistent forms of AR [3]. Available phar-
macologic options for AR include anti-histamines, LT
antagonists, and immunotherapy [4]. Since current avail-
able therapeutic agents have major adverse effects,
further research on the medical management of AR is
needed. Attention has focused on avoiding the adverse
effects of medicines traditionally used to treat AR,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Jeong et al. BMC Complementary and Alternative Medicine 2014, 14:54 Page 2 of 10
http://www.biomedcentral.com/1472-6882/14/54which has stimulated the search for effective and safe
alternatives.
The use of herbal medicines as an attractive approach
for the treatment of various inflammatory disorders has
been increasing. In an effort to find and demonstrate the
efficacy of herbal formulae used in oriental clinics for
the treatment of AR, Biyeom-Tang was evaluated for its
anti-allergic activities. Biyeom-Tang, a Korean Traditional
Medicine, composed of Xanthii Fructus (Xanthium
strumarium Linne), Trichosanthis Semen (Trichosanthe
kirilowii), Angelicae Dahuricae Radix, and Menthae Herba
(Mentha arvensis Linne var. piperascens Malinvaud), has
been used for the purpose of AR treatment in an oriental
clinic. However, its anti-allergic properties and molecular
mechanisms have not been investigated so far. The
present study demonstrated the anti-allergic effects of an
ethanol extract of Biyeom-Tang (EBT) using in vitro assays
and in vivo models.
Methods
Plant materials
Herbs (Xanthii Fructus, Trichosanthis Semen, Angelicae
Dahuricae Radix, and Menthae Herba) were purchased
from Humanherb (Gyeongsan, Korea) and a voucher
specimen has been deposited at the Korea Promotion
Institute for Tradition Medicine Industry. All herbs were
authenticated by Dr. H. Lee, a herbalist, in the Korea
Promotion Institute for Traditional Medicine Industry.
The herbs were mixed according to the ratio of com-
bination (3:3:3:1.2), extracted with 70% ethanol at a ratio
of 1:10 (w/v) and then refluxed for 24 h at 60°C. The
extracted solution was filtered and the solvent evapo-
rated under vacuum at 40°C (Eyela, Tokyo, Japan), be-
fore being freeze-dried to obtain a concentrated extract
(11.70% yield).
Preparation of bone marrow-derived mast cells (BMMC)
and assay of β-hexosaminidase (β-Hex) release
Bone marrow cells from male BALB/c mice were cultured
in 50% enriched medium (RPMI 1640 containing 2 mM
L-glutamine, 0.1 mM nonessential amino acids, antibiotics
and 10% fetal calf serum) and 20% pokeweed mitogen-
stimulated spleen condition medium as a source of IL-3.
After 3 weeks, BMMC were used for assays as the pre-
viously described procedure [5]. β-Hex was quantified
by the spectrophotometric analysis of the hydrolysis of
substrate (p-nitrophenyl-2-acetamido-2-deoxy-β-D-gluco-
pyranoside, Sigma). Briefly, BMMC (1 × 106 cells/mL)
were pre-treated with EBT for 1 h and stimulated with KL
(100 ng/mL) for 15 min. After harvesting supernatant,
cells were lysed in the same volume of medium by freeze
and thaw three times. Twenty five μL of BMMC lysate or
supernatant was mixed with 50 μl of β-Hex substrate solu-
tion (1.3 mg/mL p-nitrophenyl-2-acetamido-2-deoxy-β-D-glucopyranoside in 100 mM sodium citrate, pH 4.5) in
each well of 96-well plates and then incubated at 37°C for
60 min. The reaction was stopped by adding 175 μL of 0.2
M Glycin/NaOH (pH 10.7). The absorbance at 405 nm
was measured in a microplate reader. The percentage of
β-Hex released into the supernatant was calculated by the
following formula: [S/(S + P)] × 100, where S and P are the
β-Hex contents of supernatant and cell pellet, respectively.
Measurement of PGD2 and LTC4
To measure cyclooxygenase (COX)-2-dependent PGD2
generation by EBT, BMMC suspended at a cell density of
1 × 106 cells/mL in enriched medium were pre-incubated
with aspirin (10 μg/mL) for 2 h in order to irreversibly in-
activate pre-existing COX-1. After washing, BMMC were
activated with c-kit ligand (KL, STEMCELL Technologies.
Inc, Vancouver, BC, Canada), IL-10 (100 U/mL) and LPS
(200 ng/mL) at 37°C for 8 h in the presence or absence of
EBT and the supernatants were measured using an PGD2
assay kit (Cayman, Ann Arbor, MI, USA). For LTC4 deter-
mination, BMMC were pre-treated with EBT and stimu-
lated with KL (100 ng/mL) for 15 min. Reactions were
stopped by centrifugation at 120 g at 4°C for 5 min and
the supernatants were measured using an LTC4 assay kit
(Cayman).
Passive cutaneous anaphylaxis (PCA)
ICR mice were obtained from Koatek (Seoul, Korea) and
fed with laboratory feed (Purina, Seoul, Korea) and water
ad libitum. Mice were acclimatized in a specific pathogen-
free animal facility under conditions of 20–22°C, 40–60%
relative humidity, and a 12 h/12 h (light/dark) cycle for at
least for 7 d. For PCA, 80 ng of mouse anti-dinitrophenyl
(DNP) IgE (Sigma) was intradermally injected into one ear
of 7-week old male mice, followed 24 h later by oral
administration of EBT (100 and 200 mg/kg) or fexo-
fenadine-HCl, a histanime H1 receptor antagonist (Korea
Pharma, Seoul, 50 mg/kg). One hour later, the mice were
intravenously challenged with 60 mg of antigen (DNP-
human serum albumin (HSA); Sigma) in 200 μl of PBS
containing 1% (w/v) Evans blue. The mice were eutha-
nized 1 h after treatment with the antigen, and their ears
were removed and dissolved with 400 μl of formamide at
63°C overnight. The amount of dye extravasation was de-
termined colorimetrically at 630 nm.
Murine allergic rhinitis model and treatment
Six-week old female BALB/c mice (16–20 g) were sensi-
tized by an intraperitoneal (i.p.) administration on days 0
and 14 with 20 μg/mL of OVA in PBS mixed with an equal
volume of alum (1 mg) as an adjuvant in a total volume of
200 μL. The mice were challenged intranasally (i.n.) on
days 20 to 24 with 100 μg OVA (5 μL in PBS) into each
nostril. The EBT (50, 100, 200 mg/kg), or dexamethasone
Jeong et al. BMC Complementary and Alternative Medicine 2014, 14:54 Page 3 of 10
http://www.biomedcentral.com/1472-6882/14/54(Dex, 1 mg/kg) was per orally administered 12 times every
12 h from 1 day before the first challenge to the last chal-
lenge (Figure 1). Mice care and experimental procedures
were performed under the approval from the animal care
committee of Korea Promotion Institute for Traditional
Medicine Industry (Approval No. KOTMIN-2012-007 for
allergic rhinitis, KOTMIN-2013-013 for PCA).
Measurement of IgE and cytokines
Blood was collected 18 h after the final challenge from mice
via cardiac puncture and serum was obtained by centrifuga-
tion (1000 g for 10 min at 4°C) and stored -70°C until use.
Total serum IgE was measured by using Mouse IgE ELISA
kit (BD Biosciences, San Diego, CA, USA). The spleens
were removed and single cell suspensions (4 × 106 cells/mL)
in a complete culture medium (RPMI 1640 containing
2 mM L–glutamine, 0.1 mM nonessential amino acids,
100 U/mL of penicillin, 100 μg/mL of streptomycin and
10% fetal calf serum) were cultured in 24-well plates in
the presence of OVA (50 μg/mL). The supernatant was
collected after a 72 h culture and the protein level of cyto-
kines in the spleen culture supernatant was determined by
ELISA according to the manufacturer’s protocol (R&D
Systems, Minneapolis, MN, USA).
Histological analysis of nasal mucosa tissue
The heads of mice were excised and fixed with 10% (v/v)
formaldehyde. After fixation, the heads were decalcified
in decalcifying solution-Lite (Sigma DO818) for 3 days.
The specimens were dehydrated in various concentra-
tions of ethanol and embedded in paraffin. The sections
of the nasal mucosa were 3 μm thick and each section
was stained with hematoxylin and eosin (H&E) and the
periodic acid Schiff reagent (PAS).
HPLC analysis
The chromatographic system was composed of a Waters
1525 Binary HPLC pump and a Waters 2998 PhotodiodeFigure 1 Sensitization and challenge protocol for the experimental mArray Detector (Waters, Corp., Milford, MA, USA).
Detection and quantification were performed using Em-
power software. The separation was carried out on a
Waters Sunfire C18 column (250 mm× 4.6 mm, 5 μm) at a
column temperature of 40°C. The injection volume was 20
μL for a sample. The detection wavelength was 254 nm.
The mobile phase consisted of Solvent A (0.05% aqueous
TFA (v/v)) and Solvent B (acetonitrile) with gradient elu-
tion at the flow rate of 1 ml/min: 20% Solvent B at 0 min,
20% B at 2 min, 80% B at 46 min. Rosmarinic acid, impera-
torin, and phellopterin were commercially available from
Sigma and ChromaDex (Irvine, CA, USA).
Statistical analysis
The data are expressed as mean ± SEM. One-way ANOVA
was used to determine the statistical significance. The dif-
ferences between groups in the AR model were evaluated
by one-way ANOVA offered by Duncan’s multiple range
tests. A value of p < 0.05 was considered significant.
Results
Effect of EBT on β-Hex release and eicosanoid (PGD2 and
LTC4) production
The effects of EBT concentration (50, 100, and 200 μg/ml)
on cell viability were assessed by an MTS assay and there
was no significant change in cell viability observed in the
response to these concentrations (Figure 2A). When
mast cells are activated through IgE-dependent or IgE-
independent ways, they release preformed mediators from
their granules and produce newly synthesized eicosanoids,
chemokines and cytokines [6,7]. Degranulation was
monitored by determining the release of β-Hex because
histamine release by activated mast cells parallels the re-
lease of β-Hex. As shown in Figure 2B, pre-treatment with
EBT resulted in a dose-dependent inhibition of β-Hex re-
lease, with an IC50 value of 35.6 μg/ml. Eicosanoids such as
PGD2 and LTC4 secreted from activated mast cells have
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Figure 2 Effect of EBT on cell viability, β-Hex release, LTC4 and PGD2 productions. (A) BMMC were treated with different concentrations of
EBT and the cell viability was measured. BMMC were pre-incubated with the indicated concentrations of EBT for 1 hr and stimulated with KL (100 ng/ml)
for 15 min. Levels of (B) β-Hex and (D) LTC4 released into the supernatant were determined. (C) BMMC were pre-incubated with 10 μg/mL of aspirin for
2 h to abolish pre-existing COX-1 activity, followed by washing and then stimulation with KL/IL-10/LPS for 7 h. PGD2 released into the supernatant was
quantified. *: P < 0.05, **: P < 0.01, and ***: P < 0.001 significantly different from AR mice as determined by a one-way ANOVA.
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dependent PGD2 generation, mast cells were pre-treated
with aspirin to abolish any pre-existing COX-1 activity,
and stimulated with the KL/IL-10/LPS. The PGD2 produc-
tion was dose-dependently inhibited by EBT, with an IC50
value of 7.0 μg/ml (Figure 2C). We also assessed the inhibi-
tory activity of EBT on LTC4 production and showed that
EBT consistently inhibited LTC4 generation in a dose-
dependent manner, with an IC50 value of 10.9 μg/ml
(Figure 2D). These results suggested that EBT has COX-2/
5-LOX dual inhibitory activities.
Effect of EBT on PCA
A local extravasation was induced by a local injection of IgE
followed by an antigen challenge. We examined the anti-
allergic activity of EBT by using the PCA. An oral
administration of EBT 1 h before injection of antigen
inhibited the mast cell-mediated PCA reaction in a
dose-dependent manner (23% at 100 mg/kg and 46% at 200
mg/kg), indicating that EBT exerts anti-allergic effects
through the inhibition of mast cell degranulation (Figure 3).Effect of EBT on IgE and cytokine levels in the
OVA-induced mice
To determine the effect of EBT on the allergic re-
sponses, we measured the level of serum IgE in the
OVA-induced mice. Figure 4A shows that the level of
total IgE from serum was significantly up-regulated in
OVA-induced mice when compared to the normal mice.
However, treatment with EBT at all concentrations
tested led to a decrease in the serum level of total IgE,
indicating that EBT modulated the Th1/Th2 levels in
OVA-induced AR mice. We also evaluated the effect of
EBT on T-cell cytokine secretion by splenocyte cultures
to determine its possible effects on the T-cell response.
Figure 4B-E shows that the IL-4, IL-5, IL-10, and IL-13
levels were lower in cultures from the EBT-treated
group than in those from the OVA-induced group,
showing suppression of the Th2 response. IFN-γ se-
cretion by splenocytes from the EBT-treated mice
increased significantly in the EBT-treated mice com-
pared to that of cultures from the OVA-induced mice
(Figure 4F).
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Figure 3 Effect of EBT on systemic anaphylaxis and IgE/antigen-induced PCA reaction. (A) Mice were given an intraperitoneal injection of
compound 48/80 before EBT was orally administered. (B) EBT was administered orally 1 h prior to the challenge with antigen. Each amount of
dye was extracted and measured as described in Materials and methods. The data were expressed as the mean ± SEM (n = 6). ###: P < 0.001
significantly different from the IgE/antigen unsensitized mice mice. *: P < 0.01, **: P < 0.05 significantly different from the IgE/antigen sensitized
mice as determined by a one-way ANOVA.
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The infiltration of leukocytes and mucus secretion are
indexes of AR. We stained the nasal mucosa with H&E
and PAS staining solution to examine the inhibitory ef-
fect of EBT on histological changes in the OVA-induced
AR model. The inflammatory cells (such as mast cells
and eosinophils) in the nasal mucosa of OVA-induced
mice increased compared to those in control mice. A
marked reduction in the infiltration of inflammatory
cells was observed in the mucosa from mice that were
treated with EBT (Figure 5A). The mucous membrane
lining the nostril is shown in Figure 5B. In the OVA-
induced mice, histological analysis showed the epithelial
disruption and pre-treatment with EBT decreased the
damage to the nasal epithelium, especially at a dose of
200 mg/kg. We also examined the effect of EBT on
histological changes of the nasal mucosa by PAS stain-
ing. The mucus secretion in nasal mucosal tissue was in-
creased in the AR mice compared with the control mice
and EBT treatment reduced the mucus secretion
(Figure 5C).
HPLC analysis of EBT
The main compound profile of EBT was analyzed via
the HPLC system. The identification of six compounds
was based on the retention times and the UV spectrum
in comparison with authentic standards at a wavelength
of 254 nm. As shown in Figure 6, byakangelicol (2),oxypeucedanin (3), and isoimperatorin (6) were isolated
and purified from Angelicae dahuricae Radix by the au-
thors and the chemical structures were determined by
the comparison of their NMR spectral data with authen-
tic standards.
Discussion
In this study, we demonstrated that Biyeom-Tang, a herbal
formula used in an oriental clinic, had anti-allergic acti-
vities against degranulation and eicosanoid production in
BMMC in vitro as well as in systemic anaphylaxis, PCA
and OVA-induced AR model in vivo.
AR is an IgE-mediated inflammation characterized by
Th2 type allergic reaction, and involves eosinophil infiltra-
tion, goblet cell hyperplasia, and mast cell accumulation
in the nasal mucosa [4,9,10]. The early phase inflam-
matory response is primarily due to the release of media-
tors by mast cells. In the early allergic reaction, the
binding of antigen-IgE results in the cross-linking of FeεRI
and subsequent degranulation of the mast cells, causing
the release of active mediators such and histamine, PGs,
LTs, and cytokines which produce symptoms of sneezing,
itching and rhinorrhea. The late phase response is
essentially a cellular event. Eosinophils are the predo-
minant inflammatory cells that are activated by cytokines,
chemokines, and histamine. Cytokines produced by Th2
cells play a pivotal role in the induction and maintenance
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Figure 4 Effect of EBT on the serum IgE level and cytokine response of splenocytes. (A) Eighteen hours after the final challenge, blood was
collected by cardiac puncture to measure the serum IgE. (B-F) The splenocytes were isolated and cultured in medium with OVA (50 μg/ml).
Supernatants were collected after 72 h. The protein levels of IL-4, IL-5, IL-10, and IL-13 were determined by ELISA. The data were expressed as the
mean ± SEM (n = 6). ###: P < 0.001 significantly different from the OVA-uninduced mice. *: P < 0.05, **: P < 0.01, and ***: P < 0.001 significantly
different from AR mice as determined by a one-way ANOVA.
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allergic response except that there is more-pronounced
nasal congestion and mucus secretion.
Among effector cells, mast cells are one of the most im-
portant cells in allergic responses, such as AR [2]. Mast
cells represent a major source of histamine, proteases, and
other potent chemical mediators implicated in a wide
variety of inflammatory and immunologic process.Activated mast cells degranulate and release preformed
mediators or synthesize eicosanoid mediators from en-
dogenous membrane arachidonic acid (AA) stores [6,7].
Among the preformed mediators, β-Hex, an acid hydro-
lase, is a marker of mast cell degranulation. Bioactive LTs,
including LTB4 and cysteinyl LTs (cys-LTs, which include
LTC4, LTD4, and LTE4) play major roles in several inflam-










Figure 5 (See legend on next page.)
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Figure 5 Histological analysis of nasal mucosa tissue. Eighteen hours after the OVA challenge, the nasal mucosa tissues were removed and
histological analysis was conducted. The nasal cavities were decalcified and fixed. The sections of control (NC; PBS-induced, PC; OVA-induced) mice,
and AR mice treated with EBT or Dex were stained with H&E (A, magnification x 200; B, magnification x 200) or PAS (C, magnification x 100).
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the nuclear membrane where it colocalizes with 5- lipoxy-
genase activating protein (FLAP), and uses AA released by
cytosolic phospholipase A2 (cPLA2) as a substrate [11,12].
COX also converts AA, which is released from the plasma
membrane via the action of cPLA2, into PGH2 and then
into PGD2 [13]. In this study, the inhibitory effect of EBT
on KL-induced β-Hex release from BMMC was examined.
As shown in Figure 2A, EBT inhibited β-Hex release in a
dose dependent manner in BMMC. In addition, when
BMMC were stimulated with KL or a combination of
KL/IL-10/LPS with or without EBT, both the production
of LTC4 and PGD2 was inhibited (Figure 2C and D). These
results indicate that EBT suppresses the degranulation as
well as the production of eicosanoids (PGD2 and LTC4) in
mast cells.
Among the inflammatory mediators released from
mast cells, histamine is one of the most potent vaso-
active mediators implicated in the acute phase of imme-
diate hypersensitivity [14]. Since PCA is one of the most
important in vivo models of immediate hypersensitivity
in local allergic reactions, PCA reaction was induced by
the injection of IgE and antigen in this study. As shown
in Figure 3, oral administration of EBT 1 h prior to
challenge with antigen effectively reduced the PCA reac-
































Figure 6 HPLC chromatograms of EBT and marker compounds. (A) Th
acid; 2, Byakangelicol; 3, Oxypeucedanin; 4, Imperatorin; 5, Phellopterin; 6, Isoidemonstrated that immediate-type allergic reactions are
inhibited by EBT, indicating its role in the prevention or
treatment of mast cell-mediated allergic diseases such as
AR.
An imbalance between Th1 and Th2 responses lead to
excessive Th1 cell or Th2 cells activation. Allergic diseases
are characterized by a predominant Th2 response [15].
The allergic response in the nasal mucosa challenged with
OVA in this study includes a late phase response charac-
terized by recruitment of eosinophils, basophils, and T
cells secreting Th2 cytokines [16]. In the present study, we
successfully developed a mouse model of AR using OVA,
showing higher serum total IgE, the infiltration of inflam-
matory cells, and Th2 cytokine secretion from splenoytes
compared with the control group.
Th2 cytokines are known to play important roles in
allergic disease. Because IFN-γ has been reported to
inhibit the synthesis of IgE and the differentiation of pre-
cursor cells to Th2 cells, increased levels of IFN- γ have
been used to explain the anti-allergic effects of therapeutic
agents [17]. As shown in Figure 4B-F, we demonstrated
that EBT reduced Th2 cytokine production (IL-4, IL-5,
and IL-13) and increased Th1 cytokine (IFN- γ) pro-
duction in cultured splenocytes, showing the anti-allergic
effects of EBT. In addition, IL-10 is an inhibitory cytokine
of inflammation and it was first identified as a Th2nutes
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Th17, and regulatory T cells [18,19]. In this study, IL-10
from splenocytes decreased, demonstrating the effect of
EBT on the induction of regulatory T cells and the pro-
duction of IL-10. These results indicate that EBT could
regulate the balance of Th1/Th2 cytokine by inhibiting
the development of allergic inflammation by shifting from
a Th2 from a Th1 response in the OVA-induced AR mice.
Since IL-4 causes class switching in B cells to syn-
thesize IgE production, the decreased IL-4 secretion
from the cultured splenocytes results in reduced levels
of serum IgE. TGF-β is known to inhibit inflammatory
and immune responses through its anti-proliferative
effects on T cells and macrophages whereas it plays a
role in a signaling for fibroblast growth and activity in
wound healing [20,21]. It was also suggested that active
signaling is present in the nasal mucosa of AR and that
this may play a role in the development of goblet cell
hyperplasia in AR [22]. In this study, the level of serum
TGF-β in OVA-induced AR mice slightly decreased, but
not statistically after EBP treatment (data not shown).
Therefore, the effect of EBT on the production of
TGF-β in nasal mucosal tissue needs to be examined
further.
There were increases of infiltrated inflammatory cells,
disruption of epithelial cells, and secretion from mucous
goblet cells in the nasal tissue, indicating five-time
challenges with OVA in nostrils induced the allergic
condition (Figure 5). These histopathological changes
were alleviated by EBT treatment, suggesting that EBT is
an effect Korean Traditional Medicine in the AR mouse
model.
In our study, six compounds have been identified from
EBT so far: one phenyl propanoid (rosmarinic acid) and
five furanocoumarins (byakangelicol, oxypeudanin, impera-
torin, phellopterin and isoimperatorin). A recent study has
revealed that rosmarinic acid, a polyphenolic compound,
showed anti-inflammatory activity in the treatment of
allergic asthma [23]. The furanocoumarins also exert anti-
inflammatory activities by inhibiting NO and PGE2
production, and among these compounds, imperatorin
showed the most potent inhibitory activity [24-27]. Espe-
cially, imperatorin showed the anti-inflammatory effects by
suppressing NF-κB and MAPK kinses in LPS-stimulated
RAW 264.7 cells and a carrageenan-induced mouse paw
edema model [27,28]. Furthermore, imperatorin alleviated
the symptoms of AR in an OVA-induced mouse model
[29]. In addition, imperatorin has been known to inhibit
mucin secretion and so has possible use as a mucoregula-
tor [30]. Although these compounds might be related to
active components, other multiple compounds from EBT
may have anti-inflammatory and anti-allergic activities. We
are currently purifying other compounds from EBT to find
biologically active compounds.Conclusion
In summary, EBT exerts anti-allergic effects in an OVA-
induced AR mouse model by decreasing pharmacologically
active mediators from mast cells in vitro and alleviates
allergic rhinitis not only by suppression of Th2 cytokines
and the serum IgE level but also by the decreased infiltra-
tion of inflammatory cells in the nasal mucosa. These mul-
tiple effects might synergize to reduce AR. However, the
detailed molecular mechanisms involved and clarification
of the active compounds in EBT need to be studied in fur-
ther investigations.
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